Takeda Pharmaceutical has announced it will issue $5.5 billion of US-dollar denominated senior notes to help pay for its purchase of Shire.
In May, the firms agreed terms for a £46 billion ($62 billion) takeover of the Ireland-headquartered rare disease drugmaker.
Since that time, Takeda has raised $7.5 billion in loan agreements, as well as $4.5 billion in hybrid debt. In late October the firm said it planned to raise up to a further $18 billion in financing to replace a bridging loan.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze